Dr. John H. Sampson on the Use of Rindopepimut in Brain Cancer
Dr. John H. Sampson discusses rindopepimut elimiting brain tumor cells that express the epidermal growth factor receptor mutation variant III (EGFRvIII).
John H. Sampson, MD, PhD, MBA, MHSc, chief, Division of Neurosurgery, Duke University Medical Center, discusses rindopepimut eliminating brain tumor cells that express the epidermal growth factor receptor mutation variant III (EGFRvIII). He says tumors that do not express EGFRvIII will continue to grow and rindopepimut alone would not be effective.
In brain cancer patients where rindopepimut is not effective alone, Sampson says additing treatments like checkpoint inhibitors may allow the immune system to attack the tumor cells better.
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
